In short: Small controlled trials suggest that some topical adenosine lotions may increase the proportion of thicker hairs in adults with pattern hair loss. The studies were narrow, and a later pooled analysis did not find statistically significant differences in hair density or thick-hair proportion. Results from one lotion cannot validate every serum or shampoo.

The evidence for adenosine hair growth is encouraging but uncertain. Three small controlled studies reported improvements in hair thickness measures, yet a 2025 meta-analysis of those trials did not find a statistically significant pooled difference in hair density, thick hairs or thin hairs (Szyszkowska and Seraszek-Jaros, 2025).

These findings concern particular topical lotions used by adults with pattern hair loss. They do not show that adenosine creates new follicles, restores permanently bald areas or works in every serum and shampoo.

Which topical adenosine products have been studied?

Most clinical research concerns leave-on scalp lotions rather than rinse-off shampoos. The 2025 systematic review found seven clinical trials involving 466 participants. Six trials tested lotions and one tested a shampoo. Four tested adenosine as the sole stated active ingredient, while three used formulas that combined it with other promoted ingredients (Szyszkowska and Seraszek-Jaros, 2025).

A trial of a leave-on lotion supports claims only about the tested formula, population, comparison and follow-up. A shampoo has shorter scalp contact and a different base, while a mixed formula cannot reveal which ingredient contributed to a result. GetHair’s separate guide to caffeine shampoo covers the mixed caffeine-and-adenosine shampoo study, so its findings are not counted here as proof that adenosine alone works.

Adenosine also appears in biological and medical contexts that have nothing to do with a cosmetic scalp lotion. The evidence reviewed here does not cover injected or intravenous adenosine, medicines, transplant graft storage or general claims about adenosine triphosphate.

What did the controlled lotion trials find?

A 2008 pilot trial recruited 30 Japanese women with female pattern hair loss. The women were randomly assigned to adenosine lotion or placebo lotion in a double-blind study lasting 12 months. The abstract reports that dermatologist, investigator and participant assessments favoured adenosine. Phototrichogram results also showed increases in the anagen hair-growth rate and the proportion of thick hairs (Oura and colleagues, 2008).

This was a small pilot in one narrowly defined group. The PubMed abstract does not provide the group sizes, numerical differences or confidence intervals needed to judge the size and precision of the reported benefit. It cannot tell an individual woman how likely she is to notice a cosmetic change, and its result should not be transferred to other causes of shedding.

A 2015 double-blind randomised study enrolled 102 Japanese men with androgenetic alopecia. It compared an adenosine lotion with a niacinamide lotion for six months, rather than comparing adenosine with a plain inert base. The adenosine group did better on the investigators’ global assessment, the percentage of thick hairs measuring at least 60 micrometres, and participants’ assessment of hair thickness. The abstract also says researchers measured hair density, but it does not report a significant advantage for that endpoint (Watanabe and colleagues, 2015).

The later review treated the niacinamide lotion as equivalent to an inactive comparator for its pooled analysis, based on a separate commentary about niacinamide. That was the review authors’ analytical decision, rather than the same design as an identical lotion with only adenosine removed (Szyszkowska and Seraszek-Jaros, 2025). Several authors on the 2015 paper were affiliated with Shiseido Research Center, which also makes independent replication important (Watanabe and colleagues, 2015).

A 2016 study assessed 38 Caucasian men with androgenetic alopecia over six months. Compared with placebo, the adenosine group had a greater increase from baseline in the proportion of hairs at least 60 micrometres thick. It also had a greater reduction in the proportion of hairs under 40 micrometres and a greater change in hair density. The abstract reports statistical significance for all three comparisons (Iwabuchi and colleagues, 2016). The sample was still small, and the abstract does not provide enough detail to turn those group results into a personal forecast.

Does thicker hair mean more hairs or permanent regrowth?

Hair thickness and hair density answer different questions. In these trials, thick-hair proportion described how many measured hairs crossed a diameter threshold. Hair density described the number of hairs within a measured scalp area. A larger share of thick hairs could improve coverage even if the total number of hairs changed little. A density increase says more hairs were counted in the area, but does not by itself show that new follicles formed (Watanabe and colleagues, 2015; Iwabuchi and colleagues, 2016).

The women’s study also measured anagen hair-growth rate. Anagen describes the active growth phase, so that endpoint differs from total density and from a photograph or participant rating. Likewise, a dermatologist’s global assessment and a participant’s impression can capture visible change, but they are not direct counts of new follicles (Oura and colleagues, 2008).

None of these three abstracts reports follow-up after the study lotion ended. They therefore cannot establish that any change lasts, that a miniaturised follicle has been restored permanently or that an area without functioning follicles will regrow hair.

What does the 2025 evidence review change?

The systematic review helps reconcile positive individual reports with a cautious overall conclusion. It identified seven trials, but judged only two to provide moderate-strength evidence. Four provided low-strength evidence and one very low-strength evidence. Problems included small samples, mixed formulas, missing blinding or placebo controls, vague outcome measures and single-centre designs. Four of the seven trials were industry funded or sponsored, two declared no author conflict and one gave no statement (Szyszkowska and Seraszek-Jaros, 2025).

Only three trials were similar enough for the review’s meta-analysis. These were the 2008, 2015 and 2016 lotion studies discussed above. After six months, the pooled estimate for hair density was OR 1.03 with a 95% confidence interval from 0.89 to 1.20. For thick hairs it was OR 1.40, with an interval from 0.82 to 2.38. For thin hairs it was OR 0.93, with an interval from 0.61 to 1.43. None of the three pooled differences reached statistical significance (Szyszkowska and Seraszek-Jaros, 2025).

Statistical non-significance leaves the effect uncertain because these combined data did not separate an effect from chance at the review’s threshold. The wide interval around the thick-hair estimate allows for materially different possibilities. Small samples, different populations and the review’s decision to treat niacinamide as inactive also affect how confidently the studies can be combined.

The review’s authors concluded that the overall evidence remained low and called for better trials. The meta-analysis did not establish their suggestion that topical adenosine might be worth trying, so that editorial recommendation does not support personal treatment advice.

Can lotion results apply to any serum or shampoo?

A product name or ingredient list does not show that a retail formula matches a trial lotion. The base, other ingredients, contact time and tested population all affect whether a study is relevant. The review found adenosine concentrations ranging from 0.2% to 0.75% across the seven trials, but that range does not provide instructions for choosing or applying a product (Szyszkowska and Seraszek-Jaros, 2025).

Evidence from Japanese women, Japanese men and Caucasian men with diagnosed pattern hair loss should not be extended to every adult with thinning. The NHS hair loss guide lists illness, stress, cancer treatment, weight loss and iron deficiency among possible causes of temporary loss. A cosmetic lotion trial for pattern hair loss does not answer whether adenosine addresses any of those causes.

Risks and what can go wrong

The three controlled-study abstracts report no side effects, no causal adverse event or no treatment-related adverse effects in their small samples. Those statements describe what was recorded during those trials. They do not prove universal safety or cover uncommon reactions, larger populations, longer use or every finished formula (Oura and colleagues, 2008; Watanabe and colleagues, 2015; Iwabuchi and colleagues, 2016).

Safety reporting across the wider evidence base was incomplete. The review says several trial reports did not address adverse effects, while one separate comparison recorded folliculitis in one adenosine user and itching in another. The difference from its comparator group was not statistically significant (Szyszkowska and Seraszek-Jaros, 2025). These observations cannot supply a reliable reaction rate for products on sale.

Relying on a cosmetic product can also delay assessment of the cause. The NHS advises seeing a GP if hair loss worries you and getting an idea of the cause before approaching a commercial hair clinic (NHS: Hair loss).

Questions to ask the clinic

Talk it through

If the cause of your hair loss has been professionally assessed and you want to discuss whether restoration surgery may be an option, GetHair can arrange a free consultation with a partner clinic. The clinic assesses suitability and makes the clinical decisions.

Sources